Literature DB >> 17787027

On future non-medical costs in economic evaluations.

Bengt Liljas1, Göran S Karlsson, Nils-Olov Stålhammar.   

Abstract

Economic evaluation in health care is still an evolving discipline. One of the current controversies in cost-effectiveness analysis regards the inclusion or exclusion of future non-medical costs (i.e. consumption net of production) due to increased survival. This paper examines the implications of a symmetry rule stating that there should be consistency between costs included in the numerator and utility aspects included in the denominator. While the observation that no quality-adjusted life year (QALY) instruments explicitly include consumption and leisure seems to give support to the notion that future non-medical costs should be excluded when QALYs are used as the outcome measure, a better understanding of what respondents actually consider when reporting QALY weights is required. However, the more fundamental question is whether QALYs can be interpreted as utilities. Or more precisely, what are the assumptions needed for a general utility model also including consumption and leisure to be consistent with QALYs? Once those assumptions are identified, they need to be experimentally tested to see whether they are at least approximately valid. Until we have answers to these areas for future research, it seems premature to include future non-medical costs.

Mesh:

Year:  2008        PMID: 17787027     DOI: 10.1002/hec.1279

Source DB:  PubMed          Journal:  Health Econ        ISSN: 1057-9230            Impact factor:   3.046


  6 in total

Review 1.  Unrelated medical costs in life-years gained: should they be included in economic evaluations of healthcare interventions?

Authors:  David R Rappange; Pieter H M van Baal; N Job A van Exel; Talitha L Feenstra; Frans F H Rutten; Werner B F Brouwer
Journal:  Pharmacoeconomics       Date:  2008       Impact factor: 4.981

2.  Pharmacoeconomic guidelines should prescribe inclusion of indirect medical costs! A response to Grima et Al.

Authors:  Pieter van Baal; David Meltzer; Werner Brouwer
Journal:  Pharmacoeconomics       Date:  2013-05       Impact factor: 4.981

3.  Cost-effectiveness analysis of therapies for chronic kidney disease patients on dialysis: a case for excluding dialysis costs.

Authors:  Daniel T Grima; Lisa M Bernard; Elizabeth S Dunn; Philip A McFarlane; David C Mendelssohn
Journal:  Pharmacoeconomics       Date:  2012-11-01       Impact factor: 4.981

4.  Future Costs in Cost-Effectiveness Analyses: Past, Present, Future.

Authors:  Linda M de Vries; Pieter H M van Baal; Werner B F Brouwer
Journal:  Pharmacoeconomics       Date:  2019-02       Impact factor: 4.981

5.  Specific guidelines for assessing and improving the methodological quality of economic evaluations of newborn screening.

Authors:  Astrid Langer; Rolf Holle; Jürgen John
Journal:  BMC Health Serv Res       Date:  2012-09-04       Impact factor: 2.655

6.  The impact of healthcare costs in the last year of life and in all life years gained on the cost-effectiveness of cancer screening.

Authors:  I M C M de Kok; J J Polder; J D F Habbema; L-M Berkers; W J Meerding; M Rebolj; M van Ballegooijen
Journal:  Br J Cancer       Date:  2009-04-21       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.